Cyamemazine ( Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine chemical class which was introduced by Theraplix in France in 1972 and later in Portugal as well.
Medical use
It is used for the treatment of
schizophrenia and, especially, for
psychosis-associated
anxiety, due to its unique
anxiolytic efficacy.
It is also used to reduce anxiety associated with benzodiazepine withdrawal syndrome and anxiety in depression with suicidal tendency.
Side effects
Here are some of the most common side effects and related incidence:
Mechanism
Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of dopamine, α
1-adrenergic, H
1, and mACh receptor antagonism,
it additionally produces potent blockade of several serotonin receptors, including 5-HT
2A, 5-HT
2C, and 5-HT
7.
These actions have been implicated in cyamemazine's anxiolytic effects (5-HT
2C) and lack of extrapyramidal
(5-HT
2A),
and despite being classified as a typical antipsychotic, it actually behaves like an atypical antipsychotic.
|
H1 | 9.3 | Guinea pig | |
H2 | 351 | Guinea pig | |
H3 | 10000+ | Rat | |
M1 | 13 | Human | |
M2 | 42 | Human | |
M3 | 32 | Human | |
M4 | 12 | Human | |
M5 | 35 | Human | |
5-HT1A | 517 | Human | |
5-HT2A | 1.5 | Human | |
5-HT2C | 12 | Human | |
5-HT3 | 2943 | Human | |
5-HT7 | 22 | Human | |
D1 | 3.8 | Human | |
D2 | 5.8 | Human | |
D3 | 2.5 | Human | |
D4 | 5.3 | Human | |
α1 | 2.3 | Rat | |
α2 | 1320 | Rat | |
GABAA receptor | 10000+ | Rat | |
GABAB receptor | 10000+ | Rat | |
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. |
Synthesis
2-Cyanophenothiazine 38642-74-9 (
1)
3-Chloro-2-methylpropyl(dimethyl)amine 23349-86-2 (
2)